Thromboogenics Nv (TBGNF) 9.6000 $TBGNF
ThromboGenics Plays Long Game for Eye Disease
Catherine Shaffer, The Motley Fool - Motley Fool - Wed Mar 26, 5:30PM CDT
ThromboGenics NV recently announced that it received a 3 million euro grant from the Flemish agency for Innovation by Science and Technology to support development of new therapeutics for diabetic macular edema. The new program will complement...
ThromboGenics Acquires Exclusive Rights from Bicycle Therapeutics to Develop and Commercialize Novel Drugs Inhibiting a Target for Diabetic Macular Edema
PR Newswire Europe - Thu Sep 05, 12:31AM CDT
LEUVEN, Belgium, September 5, 2013 /PRNewswire/ --
Macular Degeneration - Pipeline Review, H2 2013 Gives an Overview of Pipeline Products for Macular Degeneration
M2 - Wed Sep 04, 12:19PM CDT
Research and Markets (http://www.researchandmarkets.com/research/wv3x9q/macular) has announced the addition of the "Macular Degeneration - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Macular Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Degeneration. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Macular Degeneration. - A review of the Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Macular Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Alcon, Inc. Genzyme Corporation Johnson & Johnson F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. Shionogi & Co., Ltd. pSivida Corp. Advanced Cell Technology, Inc. GlaxoSmithKline plc Genentech, Inc. Quark Pharmaceuticals, Inc. Pfizer Inc. iCo Therapeutics Inc. Lpath, Inc. Mesoblast Ltd BioDiem Ltd Summit Corporation plc ThromboGenics NV PolyMedix, Inc. e-Therapeutics plc NanoCarrier Co., Ltd. R-Tech Ueno, Ltd. Intellect Neurosciences, Inc. Omeros Corporation Angstrom Pharmaceuticals, Inc. Targa Therapeutics Corp. Pfenex Inc. SelectX Pharmaceuticals, Inc. Icon Bioscience, Inc. EyeGene, Inc. Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/wv3x9q/macula About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Acute Ischemic Stroke - Pipeline Review, H2 2013 Report Assists you in Identifying Players of the Most Promising Pipeline
M2 - Mon Sep 02, 12:04PM CDT
Research and Markets (http://www.researchandmarkets.com/research/jcs2gq/acute_ischemic) has announced the addition of the "Acute Ischemic Stroke - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Acute Ischemic Stroke - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Ischemic Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Ischemic Stroke. Acute Ischemic Stroke - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Acute Ischemic Stroke. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Ischemic Stroke pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - D-Pharm Ltd. - Daiichi Sankyo Company, Ltd - FCB-Pharmicell Co.,Ltd. - Gaia BioPharma Limited - Glucox Biotech - H Lundbeck A/S - M's Science Corporation - Manipal AcuNova Ltd - Mitsubishi Tanabe Pharma Corporation - Oxygen Biotherapeutics, Inc. - PhytoHealth Corporation - Reliance Life Sciences Pvt. Ltd. - Remedy Pharmaceuticals, Inc. - Sanofi-Aventis - Stem Cell Therapeutics Corp. - ThromboGenics NV For more information visit http://www.researchandmarkets.com/research/jc...e_ischemic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Health Canada Approves ThromboGenics' JETREA® for the Treatment of Symptomatic Vitreomacular Adhesion
PR Newswire - Fri Aug 16, 9:13AM CDT
Canada is first market outside the US and Europe where JETREA® is approved
Germany's IQWiG Confirms That ThromboGenics' JETREA(R) Demonstrates Major Added Value for the Treatment of Vitreomacular Traction and Macular Hole
PR Newswire Europe - Fri Aug 02, 12:31AM CDT
LEUVEN, Belgium, August 2, 2013 /PRNewswire/ --
Germany's IQWiG Confirms That ThromboGenics' JETREA® Demonstrates Major Added Value for the Treatment of Vitreomacular Traction and Macular Hole
PR Newswire - Fri Aug 02, 12:30AM CDT
ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that the German Institute for Quality and Efficiency in Health Care (IQWiG) has confirmed that JETREA® (ocriplasmin) demonstrates major / significant added value in VMT patients with mild / moderately severe symptoms compared with existing comparative treatment, when treating vitreomacular traction (VMT) including when associated with a macular hole of less than or equal to 400 microns.
ThromboGenics' JETREA(R) Receives Positive Initial NICE Recommendation for Vitreomacular Traction and Macular Hole
PR Newswire Europe - Wed Jun 12, 12:01AM CDT
LEUVEN, Belgium, June 12, 2013 /PRNewswire/ --
ThromboGenics' JETREA® Receives Positive Initial NICE Recommendation for Vitreomacular Traction and Macular Hole
PR Newswire - Wed Jun 12, 12:00AM CDT
ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that the UK's National Institute for Health and Care Excellence (NICE) has provisionally recommended JETREA® (ocriplasmin) for reimbursement within the National Health Service (NHS). The NICE Appraisal Consultation Document (ACD) initially recommends JETREA® as an option for treating vitreomacular traction (VMT) in adults, including when associated with a macular hole of less than or equal to 400 microns, when patients have severe symptoms and an epiretinal membrane is not present.
ThromboGenics Licenses Innovative Technology from Eleven Biotherapeutics to Develop Novel Drugs for the Treatment of Diabetic Eye Diseases
PR Newswire Europe - Tue May 28, 11:03AM CDT
LEUVEN, Belgium, May 28, 2013 /PRNewswire/ --
Eleven Biotherapeutics Announces Collaboration with ThromboGenics to Develop a Novel Protein Therapeutic for Ophthalmic Disease
Business Wire - Tue May 28, 10:45AM CDT
Eleven Biotherapeutics, a biopharmaceutical company creating novel and differentiated protein-based biotherapeutics for the treatment of ocular diseases, announced today that they have entered into a research collaboration and license agreement with ThromboGenics NV to research and develop a protein therapeutic based on a novel biologic target implicated in ophthalmic disease. The collaboration aims to employ Eleven's proprietary AMP-Rx protein design technology to optimize a novel therapeutic of ThromboGenics' selection to have improved pharmaceutical characteristics and therapeutic benefits. The novel biologic will be designed to treat back of the eye diseases such as diabetic macular edema.
ThromboGenics' JETREA® Launched in Denmark and Sweden
PR Newswire - Mon May 27, 10:45AM CDT
Roll out in Finland and Norway to follow shortly
ThromboGenics Business Update
PR Newswire Europe - Thu May 16, 11:16AM CDT
LEUVEN, Belgium, May 16, 2013 /PRNewswire/ --
ThromboGenics' JETREA(R) Available in Germany Public and Private Market
PR Newswire Europe - Thu May 02, 12:31AM CDT
LEUVEN, Belgium, May 2, 2013 /PRNewswire/ --
ThromboGenics' JETREA® Available in Germany Public and Private Market
PR Newswire - Thu May 02, 12:30AM CDT
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has launched JETREA® in Germany, the second European market where the product is now available.
Thrombocytopenia - Pipeline Review, H1 2013
M2 - Wed Apr 24, 5:49AM CDT
Research and Markets has announced the addition of the Thrombocytopenia - Pipeline Review, H1 2013 report to their offering. 'Thrombocytopenia - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Thrombocytopenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thrombocytopenia. Scope - A snapshot of the global therapeutic scenario for Thrombocytopenia. - A review of the Thrombocytopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Thrombocytopenia pipeline on the basis
ThromboGenics' JETREA®, the First and Only Medicine for Treating Vitreomacular Traction, now Launched in the UK
PR Newswire - Thu Apr 11, 10:45AM CDT
First EU JETREA® order triggers EUR45 million milestone payment from Alcon to ThromboGenics
ThromboGenics Starts Trading as Part of the BEL20 Index Today
PR Newswire Europe - Mon Mar 18, 1:31AM CDT
LEUVEN, Belgium, March 18, 2013 /PRNewswire/ --
ThromboGenics Plays Long Game for Eye Disease
Catherine Shaffer, The Motley Fool - Motley Fool - Wed Mar 26, 5:30PM CDT
ThromboGenics NV recently announced that it received a 3 million euro grant from the Flemish agency for Innovation by Science and Technology to support development of new therapeutics for diabetic macular edema. The new program will complement...
ThromboGenics Acquires Exclusive Rights from Bicycle Therapeutics to Develop and Commercialize Novel Drugs Inhibiting a Target for Diabetic Macular Edema
PR Newswire Europe - Thu Sep 05, 12:31AM CDT
LEUVEN, Belgium, September 5, 2013 /PRNewswire/ --
Macular Degeneration - Pipeline Review, H2 2013 Gives an Overview of Pipeline Products for Macular Degeneration
M2 - Wed Sep 04, 12:19PM CDT
Research and Markets (http://www.researchandmarkets.com/research/wv3x9q/macular) has announced the addition of the "Macular Degeneration - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Macular Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Degeneration. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Macular Degeneration. - A review of the Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Macular Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Alcon, Inc. Genzyme Corporation Johnson & Johnson F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. Shionogi & Co., Ltd. pSivida Corp. Advanced Cell Technology, Inc. GlaxoSmithKline plc Genentech, Inc. Quark Pharmaceuticals, Inc. Pfizer Inc. iCo Therapeutics Inc. Lpath, Inc. Mesoblast Ltd BioDiem Ltd Summit Corporation plc ThromboGenics NV PolyMedix, Inc. e-Therapeutics plc NanoCarrier Co., Ltd. R-Tech Ueno, Ltd. Intellect Neurosciences, Inc. Omeros Corporation Angstrom Pharmaceuticals, Inc. Targa Therapeutics Corp. Pfenex Inc. SelectX Pharmaceuticals, Inc. Icon Bioscience, Inc. EyeGene, Inc. Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/wv3x9q/macula About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Acute Ischemic Stroke - Pipeline Review, H2 2013 Report Assists you in Identifying Players of the Most Promising Pipeline
M2 - Mon Sep 02, 12:04PM CDT
Research and Markets (http://www.researchandmarkets.com/research/jcs2gq/acute_ischemic) has announced the addition of the "Acute Ischemic Stroke - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Acute Ischemic Stroke - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Ischemic Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Ischemic Stroke. Acute Ischemic Stroke - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Acute Ischemic Stroke. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Ischemic Stroke pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - D-Pharm Ltd. - Daiichi Sankyo Company, Ltd - FCB-Pharmicell Co.,Ltd. - Gaia BioPharma Limited - Glucox Biotech - H Lundbeck A/S - M's Science Corporation - Manipal AcuNova Ltd - Mitsubishi Tanabe Pharma Corporation - Oxygen Biotherapeutics, Inc. - PhytoHealth Corporation - Reliance Life Sciences Pvt. Ltd. - Remedy Pharmaceuticals, Inc. - Sanofi-Aventis - Stem Cell Therapeutics Corp. - ThromboGenics NV For more information visit http://www.researchandmarkets.com/research/jc...e_ischemic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Health Canada Approves ThromboGenics' JETREA® for the Treatment of Symptomatic Vitreomacular Adhesion
PR Newswire - Fri Aug 16, 9:13AM CDT
Canada is first market outside the US and Europe where JETREA® is approved
Germany's IQWiG Confirms That ThromboGenics' JETREA(R) Demonstrates Major Added Value for the Treatment of Vitreomacular Traction and Macular Hole
PR Newswire Europe - Fri Aug 02, 12:31AM CDT
LEUVEN, Belgium, August 2, 2013 /PRNewswire/ --
Germany's IQWiG Confirms That ThromboGenics' JETREA® Demonstrates Major Added Value for the Treatment of Vitreomacular Traction and Macular Hole
PR Newswire - Fri Aug 02, 12:30AM CDT
ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that the German Institute for Quality and Efficiency in Health Care (IQWiG) has confirmed that JETREA® (ocriplasmin) demonstrates major / significant added value in VMT patients with mild / moderately severe symptoms compared with existing comparative treatment, when treating vitreomacular traction (VMT) including when associated with a macular hole of less than or equal to 400 microns.
ThromboGenics' JETREA(R) Receives Positive Initial NICE Recommendation for Vitreomacular Traction and Macular Hole
PR Newswire Europe - Wed Jun 12, 12:01AM CDT
LEUVEN, Belgium, June 12, 2013 /PRNewswire/ --
ThromboGenics' JETREA® Receives Positive Initial NICE Recommendation for Vitreomacular Traction and Macular Hole
PR Newswire - Wed Jun 12, 12:00AM CDT
ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that the UK's National Institute for Health and Care Excellence (NICE) has provisionally recommended JETREA® (ocriplasmin) for reimbursement within the National Health Service (NHS). The NICE Appraisal Consultation Document (ACD) initially recommends JETREA® as an option for treating vitreomacular traction (VMT) in adults, including when associated with a macular hole of less than or equal to 400 microns, when patients have severe symptoms and an epiretinal membrane is not present.
ThromboGenics Licenses Innovative Technology from Eleven Biotherapeutics to Develop Novel Drugs for the Treatment of Diabetic Eye Diseases
PR Newswire Europe - Tue May 28, 11:03AM CDT
LEUVEN, Belgium, May 28, 2013 /PRNewswire/ --
Eleven Biotherapeutics Announces Collaboration with ThromboGenics to Develop a Novel Protein Therapeutic for Ophthalmic Disease
Business Wire - Tue May 28, 10:45AM CDT
Eleven Biotherapeutics, a biopharmaceutical company creating novel and differentiated protein-based biotherapeutics for the treatment of ocular diseases, announced today that they have entered into a research collaboration and license agreement with ThromboGenics NV to research and develop a protein therapeutic based on a novel biologic target implicated in ophthalmic disease. The collaboration aims to employ Eleven's proprietary AMP-Rx protein design technology to optimize a novel therapeutic of ThromboGenics' selection to have improved pharmaceutical characteristics and therapeutic benefits. The novel biologic will be designed to treat back of the eye diseases such as diabetic macular edema.
ThromboGenics' JETREA® Launched in Denmark and Sweden
PR Newswire - Mon May 27, 10:45AM CDT
Roll out in Finland and Norway to follow shortly
ThromboGenics Business Update
PR Newswire Europe - Thu May 16, 11:16AM CDT
LEUVEN, Belgium, May 16, 2013 /PRNewswire/ --
ThromboGenics' JETREA(R) Available in Germany Public and Private Market
PR Newswire Europe - Thu May 02, 12:31AM CDT
LEUVEN, Belgium, May 2, 2013 /PRNewswire/ --
ThromboGenics' JETREA® Available in Germany Public and Private Market
PR Newswire - Thu May 02, 12:30AM CDT
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has launched JETREA® in Germany, the second European market where the product is now available.
Thrombocytopenia - Pipeline Review, H1 2013
M2 - Wed Apr 24, 5:49AM CDT
Research and Markets has announced the addition of the Thrombocytopenia - Pipeline Review, H1 2013 report to their offering. 'Thrombocytopenia - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Thrombocytopenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thrombocytopenia. Scope - A snapshot of the global therapeutic scenario for Thrombocytopenia. - A review of the Thrombocytopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Thrombocytopenia pipeline on the basis
ThromboGenics' JETREA®, the First and Only Medicine for Treating Vitreomacular Traction, now Launched in the UK
PR Newswire - Thu Apr 11, 10:45AM CDT
First EU JETREA® order triggers EUR45 million milestone payment from Alcon to ThromboGenics
ThromboGenics Starts Trading as Part of the BEL20 Index Today
PR Newswire Europe - Mon Mar 18, 1:31AM CDT
LEUVEN, Belgium, March 18, 2013 /PRNewswire/ --
